We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Blood-Based Biomarkers in Alzheimer Disease: Where Are We Now and Where Have We to Go?

Christoph Laske, MD
JAMA Neurol. 2013;70(1):133-134. doi:10.1001/2013.jamaneurol.67.
Text Size: A A A
Published online


In their recent article, Doecke and colleagues1 describe the identification of a blood-based biomarker panel for classification of patients with Alzheimer disease (AD). To the strengths of this study belongs the cross-validation of the results in an independent cohort. However, there are several points that should be kept in mind when interpreting the results by Doecke et al. (1) This is the latest of a growing number of different blood-based biomarker panels with demonstrated ability to discriminate patients with AD from healthy control subjects.24 However, these panels show only in part an overlap, indicating that the perfect biomarker panel for AD diagnosis is still missing. (2) The relatively high number of 18 biomarkers in the panel bears the risk for data overfitting. (3) The specificity of the described panel should be tested by comparing patients with AD vs patients with other forms of dementia (eg, vascular dementia, Lewy body disease, and frontotemporal dementia). (4) The pathogenic relevance of the identified biomarkers should be examined by determining how the panel relates to the known AD biomarkers (cerebrospinal fluid amyloid-β and tau and/or amyloid imaging). (5) Distinguishing between patients with established AD and healthy control subjects is easy, and a marker would be of little use. On the other hand, markers of preclinical AD and/or mild cognitive impairment conversion would be of considerable use. (6) A large unmet need for the field of blood-based biomarkers to proceed to application, as has been seen in the imaging field, is the generation of standards and guidelines.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





January 1, 2013
Simon M. Laws, PhD; James D. Doecke, PhD; Ralph N. Martins, PhD
JAMA Neurol. 2013;70(1):133-134. doi:10.1001/jamaneurol.2013.709.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles

Care at the Close of Life: Evidence and Experience
Alzheimer Disease: "It's OK, Mama, If You Want to Go, It's OK"

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Supplemental Content